This article was originally published in Start Up
CombinatoRx's platform screens combinations of known drugs to find pairs that could deliver a one-two punch to diseases such as cancer and rheumatoid arthritis.
You may also be interested in...
One way for Pharma to bolster its lagging growth would be to capture some of the value of the compounds it has shelved during development. Start-ups have created technology platforms and systems biology approaches and are in place to reposition such stalled drugs in new indications, or to reformulate marketed compounds to extend the product life cycle. Nonetheless, drug firms largely remain reluctant to part even with compounds they have decided not to develop themselves. Drug makers say the issue is resources, but it is also desire. Until Big Pharma further loosens its grip on its compounds that are stalled in development, in-licensing will remain an opportunistic, case-by-case exercise, and biotechs must accept the fact that access will depend largely on advance insider knowledge of pharma firms' pipelines.
NutraGenomics Inc. is using a systems approach to identify diet-responsive genes and SNPs involved in chronic diseases such as Type 2 diabetes, obesity, atherosclerosis, and certain cancers, using proprietary mouse models to examine dietary effects on genes, proteins, transcription, and metabolism.